Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.7 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: mannitol; sodium carbonate; sodium starch glycollate; crospovidone; colloidal anhydrous silica; calcium stearate; hypromellose; macrogol 6000; sodium hydroxide; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: i) duodenal ulcer; ii) gastric ulcer; iii) gastro-oesophageal reflux disease (gord): symptomatic gord. the treatment of heartburn and other symptoms associated with gord; reflux oesophagitis; iv) gastrointestinal lesions refractory h2 blockers; v) zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.4 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: mannitol; sodium carbonate; sodium starch glycollate; crospovidone; colloidal anhydrous silica; calcium stearate; hypromellose; macrogol 6000; sodium hydroxide; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - adults 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: ? duodenal ulcer ? gastric ulcer ? gastro-oesophageal reflux disease (gord): - symptomatic gord. the treatment of heartburn and other symptoms associated with gord - reflux oesophagitis ? gastrointestinal lesions refractory to h2 blockers ? zollinger-ellison syndrome patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: ? clarithromycin and amoxicillin or ? clarithromycin and metronidazole or ? amoxicillin and metronidazole is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism (see section 4.2 dose and method of administration).,4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism.,5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.,children aged from 5 to 17 years gastro-oesophageal reflux disease (gord) ? symptomatic gord. the treatment of heartburn and other symptoms associated with gord ? reflux oesophagitis the treatment duration should not exceed 8 weeks.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.7 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: mannitol; sodium carbonate; sodium starch glycollate; crospovidone; colloidal anhydrous silica; calcium stearate; hypromellose; macrogol 6000; sodium hydroxide; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - adults 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: ? duodenal ulcer ? gastric ulcer ? gastro-oesophageal reflux disease (gord): - symptomatic gord. the treatment of heartburn and other symptoms associated with gord - reflux oesophagitis ? gastrointestinal lesions refractory to h2 blockers ? zollinger-ellison syndrome patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: ? clarithromycin and amoxicillin or ? clarithromycin and metronidazole or ? amoxicillin and metronidazole is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism (see section 4.2 dose and method of administration).,4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism.,5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.,children aged from 5 to 17 years gastro-oesophageal reflux disease (gord) ? symptomatic gord. the treatment of heartburn and other symptoms associated with gord ? reflux oesophagitis the treatment duration should not exceed 8 weeks.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: sodium stearate; carnauba wax; sodium stearylfumarate; hypromellose; iron oxide yellow; hypromellose acetate succinate; titanium dioxide; lactose monohydrate; triethyl citrate; purified talc; monoethanolamine; sodium lauryl sulfate; iron oxide red; propylene glycol; sodium starch glycollate - gastroesophageal reflux disease (gord). symptomatic gord: the relief of heartburn and other symptoms associated with gord. . erosive oesophagitis: the treatment and prevention of relapse. . peptic ulcers: the treatment of duodenal and gastric ulcer. . combination therapy for the treatment of peptic ulcer disease associated with h. pylori infection. . the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. . the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. . long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be h. pylori negative, or in whom eradication is inappropriate, e.g. the elderly or ineffective. . zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole magnesium, quantity: 20.6 mg - tablet, enteric coated - excipient ingredients: copovidone; simethicone; purified talc; glyceryl monostearate; stearic acid; polysorbate 80; titanium dioxide; colloidal anhydrous silica; propylene glycol; macrogol 6000; hypromellose; microcrystalline cellulose; magnesium stearate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; crospovidone; iron oxide red; sucrose; hydrolysed maize starch; maize starch - gastro-oesophageal reflux disease (gord). ,symptomatic gord. ,the relief of heartburn and other symptoms associated with gord.,erosive oesophagitis. ,the treatment and prevention of relapse.,peptic ulcers. ,the treatment of duodenal and gastric ulcer.,combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection.,the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs.,the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer.,long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective.,zollinger-ellison syndrome. ,the treatment of zollinger-ellison syndrome.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole magnesium, quantity: 20.6 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; propylene glycol; simethicone; stearic acid; macrogol 6000; crospovidone; titanium dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; microcrystalline cellulose; copovidone; polysorbate 80; hypromellose; purified talc; povidone; iron oxide red; maize starch; sucrose; hydrolysed maize starch - gastro-oesophageal reflux disease (gord). ,symptomatic gord. ,the relief of heartburn and other symptoms associated with gord.,erosive oesophagitis. ,the treatment and prevention of relapse.,peptic ulcers. ,the treatment of duodenal and gastric ulcer.,combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection.,the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs.,the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer.,long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective.,zollinger-ellison syndrome. ,the treatment of zollinger-ellison syndrome.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - omeprazole, quantity: 20 mg - capsule, enteric - excipient ingredients: titanium dioxide; methacrylic acid copolymer; purified water; gelatin; purified talc; iron oxide red; dibasic sodium phosphate dihydrate; hypromellose; iron oxide black; erythrosine; triethyl citrate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide - 1. symptomatic gord-the relief of heartburn and other symptoms associated with gastro-oesophageal reflux disease (gord). 2. treatment and prevention of relapse in erosive oesophagitis. 3. treatment of duodenal and gastric ulcer. 4. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. 5. treatment of gastric and duodenal ulcers and erosions associated with nonsteroidal anti-inflammatory drugs. 6. prevention of gastric and duodenal ulcers and erosions associated with nonsteoridal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 7. long-term prevention of relapse in gastric and duodenal ulceration in patients proven to be helicobacter pylori negative or in whom eradication is inappropriate (e.g. the elderly) or ineffective. 8. treatment of zollinger-ellison syndrome.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole, quantity: 20 mg - capsule - excipient ingredients: titanium dioxide; dibasic sodium phosphate; purified talc; mannitol; hypromellose; quinoline yellow; maize starch; sodium lauryl sulfate; sucrose; gelatin; polysorbate 80; macrogol 6000; purified water; methacrylic acid copolymer - the relief of heartburn and other symptoms associated with gastro-oesophageal reflux disease (gord). treatment and prevention of relapse in erosive oesophagitis. treatment of duodenal and gastric ulcer. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs (nsaids). prevention of gastric and duodenal ulcers and erosions associated with nsaids in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. long-term prevention of relapse in gastric and duodenal ulceration in patients proven to be h.pylori negative or in whom eradication is inappropriate (eg. the elderly) or ineffective. treatment of zollinger-ellison syndrome.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole, quantity: 20 mg - capsule - excipient ingredients: polysorbate 80; maize starch; mannitol; sodium lauryl sulfate; sucrose; hypromellose; macrogol 6000; purified talc; methacrylic acid copolymer; quinoline yellow; gelatin; titanium dioxide; dibasic sodium phosphate heptahydrate - the relief of heartburn and other symptoms associated with gastro-oesophageal reflux disease (gord). treatment and prevention of relapse in erosive oesophagitis. treatment of duodenal and gastric ulcer. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs (nsaids). prevention of gastric and duodenal ulcers and erosions associated with nsaids in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. long-term prevention of relapse in gastric and duodenal ulceration in patients proven to be h.pylori negative or in whom eradication is inappropriate (eg. the elderly) or ineffective. treatment of zollinger-ellison syndrome.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - omeprazole, quantity: 20 mg - capsule - excipient ingredients: maize starch; quinoline yellow; dibasic sodium phosphate; gelatin; sodium lauryl sulfate; sucrose; titanium dioxide; macrogol 6000; polysorbate 80; hypromellose; purified talc; mannitol; purified water; methacrylic acid copolymer - the relief of heartburn and other symptoms associated with gastro-oesophageal reflux disease (gord). treatment and prevention of relapse in erosive oesophagitis. treatment of duodenal and gastric ulcer. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs (nsaids). prevention of gastric and duodenal ulcers and erosions associated with nsaids in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. long-term prevention of relapse in gastric and duodenal ulceration in patients proven to be h.pylori negative or in whom eradication is inappropriate (eg. the elderly) or ineffective. treatment of zollinger-ellison syndrome.